Here we precisely link ivermectin to p-glycoprotein, and we’ve already mentioned hsp 70 on this thread. OP’s author is correct, and there is (synergy [italics]) between Ivermectin and crizotinib, linking Alzheimer’s:
Ivermectin / P-Glycoprotein
www.ncbi.nlm.nih.gov
(2016) Ivermectin-Crizotinib Synergy
www.ncbi.nlm.nih.gov
Alzheimer’s / Crizotinib
www.ncbi.nlm.nih.gov
www.ncbi.nlm.nih.gov
‘....hsp 90....vanilloid type 1....’
www.ncbi.nlm.nih.gov
There was an experimental drug for Alzheimer’s that linked vanilloid type 1 receptors to skate and a South American freshwater stingray. We’ll have to go back to the notebooks archive.
Ivermectin / P-Glycoprotein
![www.ncbi.nlm.nih.gov](https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image-v2.jpg)
Dominance of P-glycoprotein 12 in phenotypic resistance conversion against ivermectin in Caenorhabditis elegans - PubMed
While diseases caused by nematodes remains a considerable drawback for the livestock, agriculture and public health, anthelmintics drug resistance has been observed over the past years and is a major concern for parasite control. Ivermectin, initially considered as a highly potent drug...
![www.ncbi.nlm.nih.gov](https://cdn.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon.png)
(2016) Ivermectin-Crizotinib Synergy
![www.ncbi.nlm.nih.gov](https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image-v2.jpg)
Synergism between ivermectin and the tyrosine kinase/P-glycoprotein inhibitor crizotinib against Haemonchus contortus larvae in vitro - PubMed
Anthelmintic resistance is a major problem in parasitic nematodes of livestock worldwide. One means to counter resistance is to use synergists that specifically inhibit resistance mechanisms in order to restore the toxicity, and hence preserve the usefulness, of currently available...
![www.ncbi.nlm.nih.gov](https://cdn.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon.png)
Alzheimer’s / Crizotinib
![www.ncbi.nlm.nih.gov](https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image-v2.jpg)
Identification of crizotinib derivatives as potent SHIP2 inhibitors for the treatment of Alzheimer's disease - PubMed
SH2 domain-containing inositol 5'-phosphatase 2 (SHIP2) is a lipid phosphatase that produce phosphatidylinositol 3,4-bisphosphate (PI(3,4)P<sub>2</sub>) from phosphatidylinositol 3,4,5-triphosphate (PI(3,4,5)P<sub>3</sub>), and is involved in many diseases such as neurodegenerative diseases. A...
![www.ncbi.nlm.nih.gov](https://cdn.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon.png)
![www.ncbi.nlm.nih.gov](https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image-v2.jpg)
Recent Advances in Stereoselective Drug Targeting - PubMed
Reviewed here are some recent examples of medically important protein targets for which stereoselective drugs have been identified. These include heat shock protein 90 (Hsp90) inhibitors as anticancer agents; transient receptor potential vanilloid type 1 antagonists as new analgesics...
![www.ncbi.nlm.nih.gov](https://cdn.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon.png)
![www.ncbi.nlm.nih.gov](https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image-v2.jpg)
Novel Multitarget Therapies for Lung Cancer and Respiratory Disease - PubMed
In recent years, multitarget drugs for neurological diseases such as Alzheimer's disease have been developed and well researched. Many studies have revealed that multitarget drugs are also useful for lung cancer and respiratory diseases. Pemetrexed is a multitargeted antifolate with strong...
![www.ncbi.nlm.nih.gov](https://cdn.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon.png)
There was an experimental drug for Alzheimer’s that linked vanilloid type 1 receptors to skate and a South American freshwater stingray. We’ll have to go back to the notebooks archive.